chevron_leftBack
As of 6 June 2026, Prostatype Genomics AB (publ) has a market cap of $4.94M USD, ranking #44545 globally and #728 in Sweden.
It ranks #3944 in the Healthcare sector, and #832 in the Medical Devices industry.
Key Stats
Market Cap
$4.94MUSD
46.29M SEK
Enterprise Value
$3.93MUSD
37.22M SEK
Revenue (TTM)
$63.37KUSD
594.0K SEK
EBITDA (TTM)
-$3.88MUSD
-36.75M SEK
Net Income (TTM)
-$4.75MUSD
-44.5M SEK
PS Ratio
77.9
PB Ratio
1.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Fredrik Rickman
open_in_new
Employees
6
Founded
2007
Website
prostatypegenomics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.8% | 2.9% | -21% | -55% | 34% | -59% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PROGEN
Prostatype Genomics AB Ordinary Shares
ISIN: SE0023261532
Shares Out.:
Shares Outstanding:
59.189M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.8040 SEK | |
|
PGABF
Prostatype Genomics AB Ordinary Shares
ISIN: SE0023261532
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.3584 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Prostatype Genomics AB (publ)
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
STO: GETI-B
|
$5.59B
113K%
52.4B SEK
|
22.2
|
|
|
S
STO: SCIB
|
$4.85B
98K%
45.5B SEK
|
-
|
|
STO: EKTA-B
|
$2.23B
45K%
20.86B SEK
|
-
|
|
STO: VITR
|
$1.59B
32K%
14.87B SEK
|
-
|
|
STO: BONEX
|
$1.53B
31K%
14.32B SEK
|
78.5
|
|
STO: XVIVO
|
$907.38M
18K%
8.5B SEK
|
115.1
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: TMO
|
$173.27B
4M%
|
25.8
|
|
NASDAQ: ISRG
|
$160.73B
3M%
|
56.7
|
|
NYSE: ABT
|
$159.07B
3M%
|
25.6
|
|
NYSE: DHR
|
$126.55B
3M%
|
34.7
|
|
NYSE: SYK
|
$120.69B
2M%
|
38.3
|
|
NYSE: MDT
|
$101.9B
2M%
|
22.2
|
chevron_leftBack